<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00485836</url>
  </required_header>
  <id_info>
    <org_study_id>FVF4166g</org_study_id>
    <nct_id>NCT00485836</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)</brief_title>
  <acronym>CRUISE</acronym>
  <official_title>A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study
      of the efficacy and safety of intravitreal ranibizumab compared with sham injections in
      patients with macular edema secondary to central retinal vein occlusion (CRVO); 392 patients
      with CRVO were enrolled at 95 investigational sites in the United States. The study included
      a treatment period (6 months) and an observation period (6 months).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>BCVA score in the study eye was based on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Gained ≥ 15 Letters in BCVA Score at Month 6 Compared With Baseline</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>BCVA score based on the ETDRS visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Lost &lt; 15 Letters in BCVA Score at Month 6 Compared With Baseline</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>BCVA score based on the ETDRS visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Central Foveal Thickness of ≤ 250 μm at Month 6</measure>
    <time_frame>6 months</time_frame>
    <description>A central reading center assessed all optical coherence tomography (OCT) images. Central foveal thickness was defined as the center point thickness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change From Baseline in Central Foveal Thickness at Month 6</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>A central reading center assessed all OCT images. Central foveal thickness was defined as the center point thickness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Near Activities Subscale Score at Month 6</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>The NEI VFQ-25 (v. 2000; Interviewer Format) consisted of the base set of 25 questions, plus the optional additional questions (where questions A3, A4, and A5 pertained to the Near Activities Subscale). Scores ranged from 0 to 100; a higher score represented better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the NEI VFQ-25 Distance Activities Subscale Score at Month 6</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>The NEI VFQ-25 (v. 2000; Interviewer Format) consisted of the base set of 25 questions, plus the optional additional questions (where questions A6, A7, and A8 pertained to the Distance Activities Subscale). Scores ranged from 0 to 100; a higher score represented better functioning.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">392</enrollment>
  <condition>Macular Edema</condition>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Sham injection</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab injection 0.3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab injection 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham injection</intervention_name>
    <description>Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.</description>
    <arm_group_label>Sham injection</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab injection 0.3 mg</intervention_name>
    <description>Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
    <arm_group_label>Ranibizumab injection 0.3 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab injection 0.5 mg</intervention_name>
    <description>Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
    <arm_group_label>Ranibizumab injection 0.5 mg</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willingness to provide signed Informed Consent Form

          -  Age ≥ 18 years

          -  For sexually active women of childbearing potential, use of an appropriate form of
             contraception (or abstinence) for the duration of the study

          -  Ability and willingness to return for all scheduled visits and assessments

        Ocular Inclusion Criterion (Study Eye):

          -  Foveal center-involved macular edema secondary to CRVO

          -  BCVA using ETDRS charts of 20/40 to 20/320 (Snellen equivalent)

          -  Mean central subfield thickness ≥ 250 μm on two optical coherence tomography (OCT)
             measurements (at screening [confirmed by the central reading center] and Day 0
             [confirmed by the evaluating physician])

          -  Media clarity, pupillary dilation, and participant cooperation sufficient to obtain
             adequate fundus photographs

        Exclusion Criteria:

          -  History of cerebral vascular accident or myocardial infarction within 3 months prior
             to Day 0

          -  History of any anti-vascular endothelial growth factor (VEGF) or treatment in the
             fellow eye within 3 months prior to Day 0

          -  History of any systemic anti-VEGF or pro-VEGF treatment within 6 months prior to Day 0

          -  History of allergy to fluorescein

          -  History of allergy to ranibizumab injection or related molecule

          -  Relevant systemic disease that may be associated with increased systemic VEGF levels
             (namely, all active malignancies); history of successfully treated malignancies is not
             an exclusion criterion.

          -  Uncontrolled blood pressure

          -  Pregnancy or lactation

          -  Any condition that, in the opinion of the investigator, would preclude participation
             in the study (e.g., chronic alcoholism or drug abuse, personality disorder or use of
             major tranquilizers, indicated difficulty in long-term follow-up, and likelihood of
             survival of less than 1 year)

          -  Participation in an investigational trial within 30 days prior to Day 0 that involved
             treatment with any drug (excluding vitamins and minerals) or device that has not
             received regulatory approval at time of study entry

        Ocular Exclusion Criteria (Study Eye):

          -  Prior episode of retinal vein occlusion (RVO)

          -  Brisk afferent pupillary defect

          -  History of radial optic neurotomy or sheathotomy

          -  History or presence of age-related macular degeneration (AMD; dry or wet form)

          -  History of any anti-VEGF treatment in the study eye within 3 months prior to Day 0

          -  History of laser photocoagulation for macular edema within 4 months prior to Day 0

          -  History of panretinal scatter photocoagulation or sector laser photocoagulation within
             3 months prior to randomization or anticipated within the next 4 months following
             randomization

          -  History of intraocular corticosteroid use within 3 months prior to Day 0

          -  History of pars plana vitrectomy

          -  History of intraocular surgery (including cataract extraction, scleral buckle, etc.)
             within 2 months prior to Day 0 or anticipated within the next 7 months following Day 0

          -  History of yttrium-aluminum-garnet capsulotomy performed within 2 months prior to Day
             0

          -  Previous filtration surgery in the study eye

          -  History of herpetic ocular infection

          -  History of ocular toxoplasmosis

          -  History of rhegmatogenous retinal detachment

          -  History of idiopathic central serous chorioretinopathy

          -  Evidence upon examination of vitreoretinal interface disease (e.g., vitreomacular
             traction, epiretinal membrane), either on clinical examination or OCT, thought to be
             contributing to macular edema

          -  An eye that, in the investigator's opinion, would not benefit from resolution of
             macular edema, such as eyes with foveal atrophy, dense pigmentary changes, or dense
             subfoveal hard exudates

          -  Presence of an ocular condition that, in the opinion of the investigator, might affect
             macular edema or alter visual acuity during the study (e.g., uveitis or other ocular
             inflammatory disease, neovascular glaucoma, Irvine-Gass syndrome, or prior macula-off
             rhegmatogenous retinal detachment)

          -  Visually significant hemorrhage obscuring the fovea and felt to be a major contributor
             to reduced visual acuity

          -  Presence of a substantial cataract that, in the opinion of the investigator, is likely
             to be decreasing visual acuity by 3 lines or more (i.e., a 20/40 cataract)

          -  Aphakia

          -  Relevant ocular disease that may be associated with increased intraocular VEGF levels
             (namely, uveitis, neovascular glaucoma, neovascular AMD, diabetic retinopathy,
             diabetic maculopathy, or ocular ischemic syndrome)

          -  Improvement of &gt; 10 letters on best corrected visual acuity (BCVA) between screening
             and Day 0
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Rubio, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2007</study_first_submitted>
  <study_first_submitted_qc>June 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2007</study_first_posted>
  <results_first_submitted>August 16, 2010</results_first_submitted>
  <results_first_submitted_qc>February 1, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2011</results_first_posted>
  <disposition_first_submitted>May 5, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>May 5, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 7, 2010</disposition_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRVO</keyword>
  <keyword>RVO</keyword>
  <keyword>Lucentis</keyword>
  <keyword>Edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Please note that although the table below is titled &quot;Overall Study,&quot; the completion rates are for the 6-month Treatment Period only (i.e., does not include the 6-month Observation Period data).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sham Injection</title>
          <description>Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.</description>
        </group>
        <group group_id="P2">
          <title>Ranibizumab Injection 0.3 mg</title>
          <description>Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
        </group>
        <group group_id="P3">
          <title>Ranibizumab Injection 0.5 mg</title>
          <description>Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="132"/>
                <participants group_id="P3" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug (Safety Population)</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="132"/>
                <participants group_id="P3" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="129"/>
                <participants group_id="P3" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sham Injection</title>
          <description>Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.</description>
        </group>
        <group group_id="B2">
          <title>Ranibizumab Injection 0.3 mg</title>
          <description>Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
        </group>
        <group group_id="B3">
          <title>Ranibizumab Injection 0.5 mg</title>
          <description>Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="130"/>
            <count group_id="B2" value="132"/>
            <count group_id="B3" value="130"/>
            <count group_id="B4" value="392"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.4" spread="13.1"/>
                    <measurement group_id="B2" value="69.7" spread="11.6"/>
                    <measurement group_id="B3" value="67.6" spread="12.4"/>
                    <measurement group_id="B4" value="67.6" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to &lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 to &lt; 85 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 85 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="169"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months</title>
        <description>BCVA score in the study eye was based on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Intent to treat (randomized) population. Missing values were imputed using the last-observation-carried-forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Sham Injection</title>
            <description>Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab Injection 0.3 mg</title>
            <description>Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab Injection 0.5 mg</title>
            <description>Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months</title>
          <description>BCVA score in the study eye was based on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.</description>
          <population>Intent to treat (randomized) population. Missing values were imputed using the last-observation-carried-forward (LOCF) method.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" spread="14.7"/>
                    <measurement group_id="O2" value="47.4" spread="14.8"/>
                    <measurement group_id="O3" value="48.1" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Change from Baseline at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="16.2"/>
                    <measurement group_id="O2" value="12.7" spread="15.9"/>
                    <measurement group_id="O3" value="14.9" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The Hochberg-Bonferroni multiple comparison procedure was used to adjust for comparisons of the two ranibizumab groups with the sham-injection group to maintain an overall type I error rate of 0.05.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Stratified by baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters).</method_desc>
            <param_type>Difference in Least Squares means</param_type>
            <param_value>11.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.7</ci_lower_limit>
            <ci_upper_limit>15.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The Hochberg-Bonferroni multiple comparison procedure was used to adjust for comparisons of the two ranibizumab groups with the sham-injection group to maintain an overall type I error rate of 0.05.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Stratified by baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters).</method_desc>
            <param_type>Difference in Least Squares means</param_type>
            <param_value>13.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>10.3</ci_lower_limit>
            <ci_upper_limit>17.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Gained ≥ 15 Letters in BCVA Score at Month 6 Compared With Baseline</title>
        <description>BCVA score based on the ETDRS visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Intent to treat (randomized) population. Missing values were imputed using the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Sham Injection</title>
            <description>Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab Injection 0.3 mg</title>
            <description>Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab Injection 0.5 mg</title>
            <description>Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Gained ≥ 15 Letters in BCVA Score at Month 6 Compared With Baseline</title>
          <description>BCVA score based on the ETDRS visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.</description>
          <population>Intent to treat (randomized) population. Missing values were imputed using the LOCF method.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="10.5" upper_limit="23.4"/>
                    <measurement group_id="O2" value="46.2" lower_limit="37.7" upper_limit="54.7"/>
                    <measurement group_id="O3" value="47.7" lower_limit="39.1" upper_limit="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel χ²</method>
            <method_desc>Stratified by baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters).</method_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>29.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>18.8</ci_lower_limit>
            <ci_upper_limit>39.7</ci_upper_limit>
            <estimate_desc>Weighted estimates adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) using Cochran-Mantel-Haenszel weights.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel χ²</method>
            <method_desc>Stratified by baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters).</method_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>30.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>19.6</ci_lower_limit>
            <ci_upper_limit>40.9</ci_upper_limit>
            <estimate_desc>Weighted estimates adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) using Cochran-Mantel-Haenszel weights.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Lost &lt; 15 Letters in BCVA Score at Month 6 Compared With Baseline</title>
        <description>BCVA score based on the ETDRS visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Intent to treat (randomized) population. Missing values were imputed using the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Sham Injection</title>
            <description>Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab Injection 0.3 mg</title>
            <description>Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab Injection 0.5 mg</title>
            <description>Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Lost &lt; 15 Letters in BCVA Score at Month 6 Compared With Baseline</title>
          <description>BCVA score based on the ETDRS visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.</description>
          <population>Intent to treat (randomized) population. Missing values were imputed using the LOCF method.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6" lower_limit="78.4" upper_limit="90.8"/>
                    <measurement group_id="O2" value="96.2" lower_limit="93.0" upper_limit="99.5"/>
                    <measurement group_id="O3" value="98.5" lower_limit="96.3" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>Cochran−Mantel−Haenszel χ²</method>
            <method_desc>Stratified by baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters).</method_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>11.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.3</ci_lower_limit>
            <ci_upper_limit>18.2</ci_upper_limit>
            <estimate_desc>Weighted estimates adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) using Cochran-Mantel-Haenszel weights.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran−Mantel−Haenszel χ²</method>
            <method_desc>Stratified by baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters).</method_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>13.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.2</ci_lower_limit>
            <ci_upper_limit>20.1</ci_upper_limit>
            <estimate_desc>Weighted estimates adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) using Cochran-Mantel-Haenszel weights.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Central Foveal Thickness of ≤ 250 μm at Month 6</title>
        <description>A central reading center assessed all optical coherence tomography (OCT) images. Central foveal thickness was defined as the center point thickness.</description>
        <time_frame>6 months</time_frame>
        <population>Intent to treat (randomized) population. Missing values were imputed using the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Sham Injection</title>
            <description>Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab Injection 0.3 mg</title>
            <description>Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab Injection 0.5 mg</title>
            <description>Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Central Foveal Thickness of ≤ 250 μm at Month 6</title>
          <description>A central reading center assessed all optical coherence tomography (OCT) images. Central foveal thickness was defined as the center point thickness.</description>
          <population>Intent to treat (randomized) population. Missing values were imputed using the LOCF method.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" lower_limit="15.8" upper_limit="30.3"/>
                    <measurement group_id="O2" value="75.0" lower_limit="67.6" upper_limit="82.4"/>
                    <measurement group_id="O3" value="76.9" lower_limit="69.7" upper_limit="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel χ²</method>
            <method_desc>Stratified by baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters).</method_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>51.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>41.6</ci_lower_limit>
            <ci_upper_limit>62.3</ci_upper_limit>
            <estimate_desc>Weighted estimates adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) using Cochran-Mantel-Haenszel weights.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel χ²</method>
            <method_desc>Stratified by baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters).</method_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>54.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>44.0</ci_lower_limit>
            <ci_upper_limit>64.1</ci_upper_limit>
            <estimate_desc>Weighted estimates adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) using Cochran-Mantel-Haenszel weights.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute Change From Baseline in Central Foveal Thickness at Month 6</title>
        <description>A central reading center assessed all OCT images. Central foveal thickness was defined as the center point thickness.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Intent to treat (randomized) population. Missing values were imputed using the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Sham Injection</title>
            <description>Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab Injection 0.3 mg</title>
            <description>Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab Injection 0.5 mg</title>
            <description>Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change From Baseline in Central Foveal Thickness at Month 6</title>
          <description>A central reading center assessed all OCT images. Central foveal thickness was defined as the center point thickness.</description>
          <population>Intent to treat (randomized) population. Missing values were imputed using the LOCF method.</population>
          <units>μm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="687.0" spread="237.6"/>
                    <measurement group_id="O2" value="679.9" spread="242.2"/>
                    <measurement group_id="O3" value="688.7" spread="253.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Absolute Change from Baseline at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-167.7" spread="308.4"/>
                    <measurement group_id="O2" value="-433.7" spread="295.9"/>
                    <measurement group_id="O3" value="-452.3" spread="257.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Pairwise ANCOVA models adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) and baseline value of central foveal thickness.</method_desc>
            <param_type>Difference in Least Squares means</param_type>
            <param_value>-272.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-329.9</ci_lower_limit>
            <ci_upper_limit>-214.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Pairwise ANCOVA models adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) and baseline value of central foveal thickness.</method_desc>
            <param_type>Difference in Least Squares means</param_type>
            <param_value>-283.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-337.8</ci_lower_limit>
            <ci_upper_limit>-229.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Near Activities Subscale Score at Month 6</title>
        <description>The NEI VFQ-25 (v. 2000; Interviewer Format) consisted of the base set of 25 questions, plus the optional additional questions (where questions A3, A4, and A5 pertained to the Near Activities Subscale). Scores ranged from 0 to 100; a higher score represented better functioning.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Intent to treat (randomized) population; however, patients without a baseline score were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sham Injection</title>
            <description>Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab Injection 0.3 mg</title>
            <description>Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab Injection 0.5 mg</title>
            <description>Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Near Activities Subscale Score at Month 6</title>
          <description>The NEI VFQ-25 (v. 2000; Interviewer Format) consisted of the base set of 25 questions, plus the optional additional questions (where questions A3, A4, and A5 pertained to the Near Activities Subscale). Scores ranged from 0 to 100; a higher score represented better functioning.</description>
          <population>Intent to treat (randomized) population; however, patients without a baseline score were excluded from analysis.</population>
          <units>Points on the NEI VFQ-25 subscale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9" spread="22.6"/>
                    <measurement group_id="O2" value="71.2" spread="22.2"/>
                    <measurement group_id="O3" value="70.7" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="17.1"/>
                    <measurement group_id="O2" value="10.2" spread="17.4"/>
                    <measurement group_id="O3" value="9.3" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>ANCOVA</method>
            <method_desc>Pairwise ANCOVA models adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) and baseline Near Activities Subscale score.</method_desc>
            <param_type>Difference in Least Squares means</param_type>
            <param_value>5.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.1</ci_lower_limit>
            <ci_upper_limit>9.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0099</p_value>
            <method>ANCOVA</method>
            <method_desc>Pairwise ANCOVA models adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) and baseline Near Activities Subscale score.</method_desc>
            <param_type>Difference in Least Squares means</param_type>
            <param_value>4.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>8.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the NEI VFQ-25 Distance Activities Subscale Score at Month 6</title>
        <description>The NEI VFQ-25 (v. 2000; Interviewer Format) consisted of the base set of 25 questions, plus the optional additional questions (where questions A6, A7, and A8 pertained to the Distance Activities Subscale). Scores ranged from 0 to 100; a higher score represented better functioning.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Intent to treat (randomized) population; however, patients without a baseline score were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sham Injection</title>
            <description>Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab Injection 0.3 mg</title>
            <description>Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab Injection 0.5 mg</title>
            <description>Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the NEI VFQ-25 Distance Activities Subscale Score at Month 6</title>
          <description>The NEI VFQ-25 (v. 2000; Interviewer Format) consisted of the base set of 25 questions, plus the optional additional questions (where questions A6, A7, and A8 pertained to the Distance Activities Subscale). Scores ranged from 0 to 100; a higher score represented better functioning.</description>
          <population>Intent to treat (randomized) population; however, patients without a baseline score were excluded from analysis.</population>
          <units>Points on the NEI VFQ-25 subscale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0" spread="22.5"/>
                    <measurement group_id="O2" value="77.3" spread="19.8"/>
                    <measurement group_id="O3" value="77.0" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="15.6"/>
                    <measurement group_id="O2" value="8.9" spread="13.7"/>
                    <measurement group_id="O3" value="6.7" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <method_desc>Pairwise ANCOVA models adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) and baseline Distance Activities Subscale score.</method_desc>
            <param_type>Difference in Least Squares means</param_type>
            <param_value>6.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.1</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0199</p_value>
            <method>ANCOVA</method>
            <method_desc>Pairwise ANCOVA models adjusted for baseline visual acuity score (≤ 34, 35-54, ≥ 55 letters) and baseline Distance Activities Subscale score.</method_desc>
            <param_type>Difference in Least Squares means</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>7.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Investigators assessed the occurrence of AE/SAEs at all study visits. Summaries are for the safety-evaluable population and include events regardless of relation to study drug or location (e.g. non-study eye events are included). For each AE/SAE, the number of patients experiencing the event, not the number of occurrences of the event, is reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sham Injection</title>
          <description>Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.</description>
        </group>
        <group group_id="E2">
          <title>Ranibizumab Injection 0.3 mg</title>
          <description>Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
        </group>
        <group group_id="E3">
          <title>Ranibizumab Injection 0.5 mg</title>
          <description>Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis Coronary Artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate Antidiuretic Hormone Secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness Unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Vitreous Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Corneal Edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Iris Neovascularization</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Retinal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Macular Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Retinal Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Retinal Vascular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Retinal Vascular Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Retinal Vein Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Retinal Depigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Macular Edema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food Allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lead Dislodgement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Gastric Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Venous Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="111" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Foreign Body Sensation in Eyes</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Iris Neovascularization</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Macular Edema</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Myodesopsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Ocular Vascular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Optic Disc Vascular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Retinal Depigmentation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Retinal Exudates</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Retinal Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Retinal Pigmentation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Retinal Vascular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Vitreous Detachment</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Vitreous Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Genentech, Inc.</organization>
      <phone>800-821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

